WO2008014108A2 - Antimicrobial oxazolidinone prodrugs - Google Patents

Antimicrobial oxazolidinone prodrugs Download PDF

Info

Publication number
WO2008014108A2
WO2008014108A2 PCT/US2007/073095 US2007073095W WO2008014108A2 WO 2008014108 A2 WO2008014108 A2 WO 2008014108A2 US 2007073095 W US2007073095 W US 2007073095W WO 2008014108 A2 WO2008014108 A2 WO 2008014108A2
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
oxazolidin
pyrrolo
pyrazol
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/073095
Other languages
French (fr)
Other versions
WO2008014108A3 (en
Inventor
Mark J. Macielag
Manomi A. Tennakoon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38870255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008014108(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of WO2008014108A2 publication Critical patent/WO2008014108A2/en
Publication of WO2008014108A3 publication Critical patent/WO2008014108A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to compounds that are prodrugs of antimicrobial oxazolidinones.
  • the invention also relates to pharmaceutical formulations of the compounds, and to methods of using the compounds to treat patients afflicted with various bacterial infections.
  • Oxazolidinones are identified as a class of synthetic antimicrobial compounds, and possess activity against a variety of pathogens. Because of the increasing development of bacterial resistance to many antibiotics, oxazolidinones will play an important role in the treatment of infections.
  • variable moieties in Formula (A) are as described in the specification of the above-referenced published application. Forty-two specific compounds were identified as compounds that were synthesized and that fall within the limits of Formula (A).
  • the invention relates to oxazolidinone prodrug compounds having the Formula (I):
  • Compound 1 is described in detail in United States Patent 6,413,981, which is incorporated herein by reference.
  • the invention also relates to oxazolidinone prodrugs of Formula (II):
  • R 1 is hydrogen or lower alkyl
  • R 2 is selected from the group consisting of
  • n 0, 1 , 2, 3 or 4;
  • X is selected from the group consisting of amino optionally substituted by one or two lower alkyl; heterocyclyl optionally substituted by one or more lower alkyl; and
  • Y is selected from the group consisting of -CH2O-PO3H2 or an alkyl ester thereof, and -O-PO3H2 or an alkyl ester thereof;
  • R 3 is hydrogen or lower alkyl; or a pharmaceutically acceptable salt thereof.
  • This invention also relates to pharmaceutical formulations including an oxazolidinone prodrug of Formula (I) or (II) as active pharmaceutical ingredient, and one or more pharmaceutically acceptable excipients, diluents, fillers, or the like to form a solid or liquid dosage form adapted for administration by oral or parenteral routes to warm- blooded mammals, including humans.
  • the invention also relates to methods for treating patients suffering from microbial diseases by administering an effective amount of a compound of Formula (I) or (II) or a pharmaceutical formulation comprising a Formula (I) or (II) compound and one or more pharmaceutically acceptable excipients, diluents, fillers, or the like.
  • the oxazolidinone prodrugs of Formula (II) include compounds wherein: R 1 is hydrogen or lower alkyl;
  • R 2 is selected from the group consisting of
  • X is selected from the group consisting of amino optionally substituted by one or two lower alkyl; and, heterocyclyl, optionally substituted by one or more lower alkyl;
  • R 3 is lower alkyl; or a pharmaceutically acceptable salt thereof.
  • the oxazolidinone prodrugs of Formula (II) include compounds wherein: R 1 is hydrogen or methyl;
  • R 2 is selected from the group consisting of
  • n 1 ;
  • X is selected from the group consisting of amino optionally substituted by one or two methyl; and, pyrrolidinyl, piperazinyl or morpholinyl, optionally substituted on pyrrolidinyl or piperazinyl by one methyl;
  • R 3 is ethyl; or a pharmaceutically acceptable salt thereof.
  • the oxazolidinone prodrugs of Formula (II) include compounds wherein X is selected from the group consisting of amino optionally substituted by one or two methyl; and, piperazinyl optionally substituted by one methyl.
  • “Lower alkyl” means a fully saturated straight chain or branched chain hydrocarbon containing from one to no more than eight total carbon atoms.
  • Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, t-butyl, and others.
  • “Heterocyclyl” means a cyclic moiety of one or more rings, fused or unfused, wherein at least one ring atom is a non-carbon atom. Preferred heteroatoms include oxygen, nitrogen, sulfur and phosphorus, or any combination of two or more of those atoms. Examples of heterocyclic groups include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, and others. "Optionally substituted by” means the substitution of the listed groups for one or more hydrogen atoms thereof.
  • Prodrug means a precursor to a pharmaceutically active drug, which is converted into the active drug in the body by normal metabolic processes.
  • “Pharmaceutically acceptable salt” means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.
  • Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, o-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1 ,2- ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic
  • an alkali metal ion an alkaline earth ion, or an aluminum ion ; or coordinates with an organic base such as ethanolamine, triethanolamine, tromethamine, N- methylglucamine, and the like.
  • Compounds of this invention according to Formula (I) or Formula (II) are useful as prodrugs of the active ingredient (Compound 1) disclosed above.
  • the oxazolidinone prodrugs of Formula (II) include compounds selected from the group consisting of:
  • the oxazolidinone prodrugs of Formula (II) include compounds selected from the group consisting of:
  • the oxazolidinone prodrugs of Formula (II) include compounds selected from the group consisting of:
  • Compound 1 is possessed of antimicrobial properties as described in United States Patent 6,413,981, which is incorporated herein by reference.
  • compounds of this invention include the following:
  • the compounds of Formula (II) may be prepared from Compound 1, the synthesis of Compound 1 is described in US 6,413,981. Outlined in Schemes 1 through 5 are representative procedures to prepare the compounds of the instant invention.
  • Scheme 1 illustrates the method of synthesis of the chloroalkoxycarbonyl precursors (2) to the compounds of the invention.
  • Compound 1 is reacted with a chloroalkyl chloro formate derivative in the presence of a base.
  • bases include sodium hexamethyldisilazide, potassium hexamethyldisilazide, lithium diisopropylamide (LDA), lithium tetramethylpiperidide, l,8-diazabicyclo[5.4.0]undec-7-ene (DBU), tetramethylguanidine, and others.
  • the reaction is preferably run for between 30 min to 24 h in an inert solvent such as THF, dioxane, 1 ,2-dimethoxyethane (DME), or DMF at a temperature ranging from -78 0 C to 80 0 C.
  • an inert solvent such as THF, dioxane, 1 ,2-dimethoxyethane (DME), or DMF at a temperature ranging from -78 0 C to 80 0 C.
  • Scheme 2 depicts the conversion of the chloroalkoxycarbonyl derivatives (2) from Scheme 1 to a variety of compounds of the instant invention, including the substituted acyloxymethoxycarbonyl derivatives of Formula (III), wherein R 1 , X and n are as defined above.
  • derivative 2 is reacted with an alkali metal (preferably cesium) salt of an appropriately substituted carboxylic acid derivative.
  • the reaction is optionally performed in the presence of an iodide salt, such as potassium iodide or sodium iodide, in a suitable solvent such as DMF, acetonitrile, or DMSO.
  • the reaction is performed at a temperature ranging from 0 0 C to 100 0 C for from 2 h to 48 h.
  • a protecting group is present in the compound of Formula (III), it may optionally be removed by methods known to those skilled in the art to provide compounds of Formula (III) in which the protecting group has been replaced by a hydrogen atom.
  • Amine protecting groups include, but are not limited to, tert-butyloxycarbonyl (Boc), which may be removed under acidic conditions, for example by treatment with trifluoroacetic acid in DCM or HCl in ethyl ether, and carbobenzyloxy (Cbz), which may be removed by hydrogeno lysis.
  • Phosphate protecting groups include, but are not limited to, tert-butyi ( 1 Bu), which may be removed under acidic conditions, such as by treatment with trifluoroacetic acid in DCM or HCl in ethyl ether, and benzyl (Bn), which may be removed by hydrogenolysis.
  • Scheme 3 illustrates the synthesis of compounds of Formula IV from derivative Compound 2.
  • the process is similar to the one described in Scheme 2.
  • Derivative Compound 2 is reacted with an alkali metal (preferably cesium) salt of a suitably substituted benzoic acid derivative to provide compounds of Formula (IV).
  • an alkali metal (preferably cesium) salt of a suitably substituted benzoic acid derivative to provide compounds of Formula (IV).
  • the reaction is conducted in a suitable solvent, such as DMF, acetonitrile, or DMSO at a temperature ranging from 0 0 C to 100 0 C for from 2 h to 48 h, optionally in the presence of an iodide salt, such as potassium iodide or sodium iodide.
  • a protecting group is present in the compounds of Formula (IV), it may optionally be removed by methods known to those skilled in the art to provide compounds of Formula (IV) in which the protecting group has been replaced by a hydrogen atom.
  • Phosphate protecting groups include, but are not limited to, tert-butyi ( 1 Bu), which may be removed under acidic conditions, such as by treatment with trifluoroacetic acid in DCM or HCl in ethyl ether, and benzyl (Bn), which may be removed by hydrogeno lysis .
  • Scheme 4 illustrates the synthesis of phosphate ester compounds of Formula (V) from derivative Compound 2.
  • derivative Compound 2 is reacted with a suitably protected salt of a phosphoric acid diester derivative.
  • the reaction is optionally performed in the presence of an iodide salt, such as potassium iodide or sodium iodide, in an appropriate solvent, such as DMF, THF, or DMSO.
  • the reaction is preferably performed at a temperature ranging from 0 0 C to 100 0 C for from 2 h to 96 h, followed by removal of the PG 1 protecting group to provide compounds of Formula (V) wherein R is lower alkyl.
  • Preferred phosphate salts are those in which Z + is tetraalkylammonium, which may be prepared by exchange of the t-butylamine salt with a tetraalkylammonium hydroxide derivative.
  • Phosphate protecting groups include, but are not limited to, tert-butyi ( 1 Bu), which may be removed under acidic conditions, such as by treatment with trifluoroacetic acid in DCM or HCl in ethyl ether, and benzyl (Bn), which may be removed by hydrogeno lysis.
  • Scheme 5 illustrates the synthesis of phosphate compounds of Formula (VI) from derivative Compound 2.
  • derivative Compound 2 is reacted with a suitably protected salt of a phosphoric acid diester derivative to produce compounds of Formula (VI).
  • the reaction is optionally performed in the presence of an iodide salt, such as potassium iodide or sodium iodide, in an appropriate solvent, such as DMF, THF, or DMSO, at a temperature ranging from 0 0 C to 100 0 C for from 2 h to 96 h, followed by removal of the PG 1 protecting groups.
  • Preferred phosphate salts are those in which Z + is tetraalkylammonium.
  • Phosphate protecting groups include, but are not limited to, tert- butyl ( 1 Bu), which may be removed under acidic conditions, such as by treatment with trifluoroacetic acid in DCM or HCl in ethyl ether, and benzyl (Bn), which may be removed by hydrogenolysis.
  • tert- butyl ( 1 Bu) which may be removed under acidic conditions, such as by treatment with trifluoroacetic acid in DCM or HCl in ethyl ether
  • Bn benzyl
  • reaction mixture was then filtered and purified directly by HPLC (C- 18 column, 30- 90% gradient elution, MeCN : H 2 O), and fractions containing product were lyophilized to give 0.670 g, (33%) of the title compound as a fluffy white solid.
  • Example 5 4-[ 1 -(Acetyl- ⁇ (R)-3-[3-fiuoro-4-(2-methyl-2,6-dihydro-4/f- pyrrolo[3,4c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl ⁇ - carbamoyloxy)-ethoxycarbonylmethyl]-piperazine- 1 -carboxylic acid tert-butyl ester (3b)
  • reaction mixture was then filtered and purified directly by HPLC (C- 18 column, 30-90% gradient elution, MeCN : H 2 O), and fractions containing product were lyophilized to give 95 mg (11%) of the title compound as a mixture of diastereomers.
  • Morpholin-4-yl-acetic acid (acetyl- ⁇ (R)-3-[3-fluoro-4-(2-methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl ⁇ -carbamoyloxy)-methyl ester (6)
  • the first step in this reaction sequence was carried out according to a procedure described in Gray, M. D. M.; Smith, D. J. H. Tetrahedron. Lett. 1980, 21, 859.
  • a solution of phosphoric acid dibenzyl ester ethyl ester (5.22 g, 17.05 mmol) in te/t-butylamine (10 mL) was heated at 92 0 C (oil bath temperature) in a sealed tube for 8 h. Upon cooling to rt a white waxy solid formed. To this solid was added tetrabutylammonium hydroxide (11.37 mL, 17.05 mmol) and the resulting homogenous solution was extracted three times with diethyl ether.
  • Step 1 To a solution of benzyl glycolate (2.0 mL, 14.1 mmol) and triethylamine (2.35 mL, 16.9 mmol) in dichloromethane (30 mL) at 0 0 C was added dropwise methanesulfonyl chloride (1.20 mL, 15.1 mL). The reaction was stirred overnight, diluted with dichloromethane, washed with saturated aqueous NH 4 Cl, and then with saturated NaHC ⁇ 3, dried with Na 2 SO 4 , and concentrated in vacuo to give 2.50 g (73%) of methanesulfonyloxy-acetic acid benzyl ester which was used in the next step without further purification.
  • Step 2 To a solution of methanesulfonyloxy-acetic acid benzyl ester (2.50 g, 10.24 mmol) in THF (20 mL) was added the tetrabutylammonium salt of di-te/t-butylphosphate (4.61 g, 10.24 mmol). The reaction was stirred overnight, concentrated, and purified directly by MPLC (SiO 2 , 10-30% gradient elution, Hexane : EtOAc) to give 1.42 g (39%) of (di-tert-butoxy-phosphoryloxy)-acetic acid benzyl ester.
  • Step 3 (Di-tert-butoxy-phosphoryloxy)-acetic acid benzyl ester (700 mg, 1.96 mmol) was dissolved in MeOH (40 rnL) and passed through a "H-cube" hydrogenator with a 10% Pd on carbon cartridge under 40 psi of hydrogen at a flow rate of 1 mL/min.
  • Step 4 To a solution of (di-tert-butoxy-phosphoryloxy)-acetic acid (480 mg, 1.79 mmol) in MeOH (4 mL) and water (2 mL) was added cesium carbonate (261 mg, 0.80 mmol) and the reaction was stirred at rt for 10 min. The resulting homogenous solution was concentrated in vacuo to give the title compound as a gummy solid.
  • the solubility of the active drug, Compound 1 was determined in a separate experiment in which an excess of the compound was added to pH 4 buffer. The mixture was shaken with a Burrell wrist action shaker at ambient temperature for 24 hours. Excess solute was removed by centrifugation, the supernatant was diluted with a suitable solvent, and the concentration of the compound was measured using HPLC. The solubility of Compound 1 at pH 4 was 0.007 mg/mL.
  • mice Female Swiss Webster mice weighing between 20-25 g were infected intraperitoneally with approximately 5x10 5 colony forming units (CFU) S. aureus Smith in 7% mucin. One hour later, the animals were given prodrug or Compound 1 intravenously or orally in a dose volume of 0.1 mL/lOg body weight. Each group consisted of eight animals.
  • the prodrugs were prepared immediately before dosing in 40 mM sodium citrate buffer, pH 4. Compound 1 was prepared in 20% HP ⁇ CD and warmed until dissolved (IV dosing) or in 0.5% methocel (PO dosing) as a suspension. The mice were observed over a three day period and ED50 values were calculated from the resulting % survival curves (Table 2). The term "ND" means not determined.
  • the prodrug ED 50 values were normalized to the content of Compound 1.
  • prodrug intravenously (mice, rats, or dogs) or orally (mice).
  • the prodrugs were prepared immediately before dosing in 40 mM sodium citrate buffer, pH 4.
  • Compound 1 was prepared in 20% HP ⁇ CD and warmed until dissolved (IV dosing), or in 0.5% methocel as a suspension (PO dosing).
  • IV dosing dissolved (IV dosing)
  • PO dosing 0.5% methocel as a suspension
  • blood was removed (via cardiac puncture in euthanized mice, via orbital sinus puncture in anesthetized rats, or via cephalic vein in conscious dogs) and 200 DL of the plasma supernatant was immediately frozen (-70 0 C).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

This invention includes oxazolidinone prodrug compounds of Formula (I) and Formula (II) as defined herein. The prodrugs are convertible by natural biological processes into an active ingredient possessed of antimicrobial properties useful in treating bacterial infections in mammals.

Description

ANTIMICROBIAL OXAZOLIDINONE PRODRUGS CROSS REFERENCE TO RELATED APPLICATIONS
This present application claims benefit of U.S. Provisional Patent Application Serial No. 60/820497, filed July 27, 2006 and U.S. Provisional Patent Application Serial No. 60/848659, filed October 2, 2006, which are incorporated herein by reference in their entirety and for all purposes.
FIELD OF THE INVENTION
This invention relates to compounds that are prodrugs of antimicrobial oxazolidinones. The invention also relates to pharmaceutical formulations of the compounds, and to methods of using the compounds to treat patients afflicted with various bacterial infections.
BACKGROUND OF THE INVENTION
Oxazolidinones are identified as a class of synthetic antimicrobial compounds, and possess activity against a variety of pathogens. Because of the increasing development of bacterial resistance to many antibiotics, oxazolidinones will play an important role in the treatment of infections.
Issues common to many oxazolidinones have been low absorption rate and poor water solubility. The development and administration of prodrugs can at times improve the pharmacological properties of oxazolidinones, as well as other drugs. Development of prodrugs is also often geared to enhancing water solubility, which simplifies the development of pharmaceutical formulations intended for intravenous administration. International Publication Number WO 2005/028473, published March 31, 2005, identifies some possible prodrugs for certain oxazolidinones, namely acyloxymethylcarbamate derivatives according to the Formula (A) disclosed in the above publication:
Figure imgf000003_0001
(A)
The variable moieties in Formula (A) are as described in the specification of the above-referenced published application. Forty-two specific compounds were identified as compounds that were synthesized and that fall within the limits of Formula (A).
SUMMARY OF THE INVENTION
The invention relates to oxazolidinone prodrug compounds having the Formula (I):
Figure imgf000003_0002
(I) wherein R is a leaving group that undergoes a reaction in a biological matrix to produce the active ingredient of the structure of Compound 1:
Figure imgf000003_0003
Compound 1
Compound 1 is described in detail in United States Patent 6,413,981, which is incorporated herein by reference. The invention also relates to oxazolidinone prodrugs of Formula (II):
Figure imgf000004_0001
(H) wherein:
R1 is hydrogen or lower alkyl;
R2 is selected from the group consisting of
Figure imgf000004_0002
wherein, n is 0, 1 , 2, 3 or 4;
X is selected from the group consisting of amino optionally substituted by one or two lower alkyl; heterocyclyl optionally substituted by one or more lower alkyl; and
-O-PO3H2 or an alkyl ester thereof;
Y is selected from the group consisting of -CH2O-PO3H2 or an alkyl ester thereof, and -O-PO3H2 or an alkyl ester thereof;
R3 is hydrogen or lower alkyl; or a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutical formulations including an oxazolidinone prodrug of Formula (I) or (II) as active pharmaceutical ingredient, and one or more pharmaceutically acceptable excipients, diluents, fillers, or the like to form a solid or liquid dosage form adapted for administration by oral or parenteral routes to warm- blooded mammals, including humans. The invention also relates to methods for treating patients suffering from microbial diseases by administering an effective amount of a compound of Formula (I) or (II) or a pharmaceutical formulation comprising a Formula (I) or (II) compound and one or more pharmaceutically acceptable excipients, diluents, fillers, or the like.
DETAILED DESCRIPTION OF THE INVENTION
In embodiments of the present invention, the oxazolidinone prodrugs of Formula (II) include compounds wherein: R1 is hydrogen or lower alkyl;
R2 is selected from the group consisting of
O O
/C-(CH2)n-X; and "^P-OR3 OH , wherein n is 1 ;
X is selected from the group consisting of amino optionally substituted by one or two lower alkyl; and, heterocyclyl, optionally substituted by one or more lower alkyl;
R3 is lower alkyl; or a pharmaceutically acceptable salt thereof.
In an embodiment of the present invention, the oxazolidinone prodrugs of Formula (II) include compounds wherein: R1 is hydrogen or methyl;
R2 is selected from the group consisting of
O O
/C-(CH2)n-X; and "^P-OR3 OH , wherein n is 1 ; X is selected from the group consisting of amino optionally substituted by one or two methyl; and, pyrrolidinyl, piperazinyl or morpholinyl, optionally substituted on pyrrolidinyl or piperazinyl by one methyl;
R3 is ethyl; or a pharmaceutically acceptable salt thereof.
In an embodiment of the present invention, the oxazolidinone prodrugs of Formula (II) include compounds wherein X is selected from the group consisting of amino optionally substituted by one or two methyl; and, piperazinyl optionally substituted by one methyl.
Definitions
As used herein, these terms of art have the following meaning:
"Lower alkyl" means a fully saturated straight chain or branched chain hydrocarbon containing from one to no more than eight total carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, t-butyl, and others. "Heterocyclyl" means a cyclic moiety of one or more rings, fused or unfused, wherein at least one ring atom is a non-carbon atom. Preferred heteroatoms include oxygen, nitrogen, sulfur and phosphorus, or any combination of two or more of those atoms. Examples of heterocyclic groups include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, and others. "Optionally substituted by" means the substitution of the listed groups for one or more hydrogen atoms thereof.
"Prodrug" means a precursor to a pharmaceutically active drug, which is converted into the active drug in the body by normal metabolic processes.
"Pharmaceutically acceptable salt" means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, o-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1 ,2- ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4- chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]oct-2-ene-l-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis(3-hydroxy-2-ene-l-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e. g. , an alkali metal ion, an alkaline earth ion, or an aluminum ion ; or coordinates with an organic base such as ethanolamine, triethanolamine, tromethamine, N- methylglucamine, and the like.
Compounds of this invention according to Formula (I) or Formula (II) are useful as prodrugs of the active ingredient (Compound 1) disclosed above.
In an embodiment of the present invention, the oxazolidinone prodrugs of Formula (II) include compounds selected from the group consisting of:
Cpd Name
4a Piperazin-1-yl-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2,6-dihydro-4H- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
4b Piperazin-1-yl-acetic acid 1 -(acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2, 6-dihydro-
4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-ethyl ester,
5 Dimethylamino-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2, 6-dihydro-4H- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
6 Morpholin-4-yl-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2, 6-dihydro-4/f- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
7 l-Methyl-pyrrolidine-2-carboxylic acid (acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester, Cpd Name (4-Methyl-piperazin-l-yl)-acetic acid (acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester, (tert-Butoxycarbonyl-methyl-amino)-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2- methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl} -carbamoyloxy)-methyl ester, 0 Methylamino-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2,6-dihydro-4H- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester, 1 (S)-Pyrrolidine- 1 ,2-dicarboxylic acid 2-[(acetyl- {(R)-3-[3-fluoro-4-(2-methyl- 2,6-dihydro-4/f-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl}-carbamoyloxy)-methyl] ester l-tert-buty{ ester, 2 (S)-Pyrrolidine-2-carboxylic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester, 3 4-(Bis-benzyloxy-phosphoryloxymethyl)-benzoic acid (acetyl- {(R)-3-[3-fluoro- 4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl} -carbamoyloxy)-methyl ester, 4 4-Phosphonooxymethyl-benzoic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2, 6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester, 5 4-(Bis-benzyloxy-phosphoryloxy)-benzoic acid (acetyl- {(R)-3-[3-fluoro-4-(2- methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl} -carbamoyloxy)-methyl ester, 6 4-Phosphonooxy-benzoic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2, 6-dihydro- 4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester, 7a Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid di-tert-butoxy- phosphoryloxymethyl ester, 7b Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid 1 -(di-te/t-butoxy- phosphoryloxy)-ethyl ester, 8a Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid phosphonooxymethyl ester, 8b Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid 1 -phosphonooxy-ethyl ester, Cpd Name
20a Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid benzyloxy-ethoxy- phosphoryloxymethyl ester,
20b Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid 1 -(benzyloxy-ethoxy- phosphoryloxy)-ethyl ester,
21a Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid ethoxy-hydroxy- phosphoryloxymethyl ester,
21b Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid 1 -(ethoxy-hydroxy- phosphoryloxy)-ethyl ester,
23 (Di-tert-butoxy-phosphoryloxy)-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl- 2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl}-carbamoyloxy)-methyl ester, and
24 Phosphonooxy-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2,6-dihydro-4H- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester.
In an embodiment of the present invention, the oxazolidinone prodrugs of Formula (II) include compounds selected from the group consisting of:
Cpd Name
4a Piperazin-1-yl-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2,6-dihydro-4H- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
4b Piperazin-1-yl-acetic acid 1 -(acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2, 6-dihydro-
4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-ethyl ester,
5 Dimethylamino-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2, 6-dihydro-4H- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
6 Morpholin-4-yl-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2, 6-dihydro-4/f- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
7 l-Methyl-pyrrolidine-2-carboxylic acid (acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester, Cpd Name
8 (4-Methyl-piperazin-l-yl)-acetic acid (acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
10 Methylamino-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2,6-dihydro-4H- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
12 (S)-Pyrrolidine-2-carboxylic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2, 6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
14 4-Phosphonooxymethyl-benzoic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2, 6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
16 4-Phosphonooxy-benzoic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2, 6-dihydro-
4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
18a Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid phosphonooxymethyl ester,
18b Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid 1 -phosphonooxy-ethyl ester,
21a Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid ethoxy-hydroxy- phosphoryloxymethyl ester,
21b Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid 1 -(ethoxy-hydroxy- phosphoryloxy)-ethyl ester, and
24 Phosphonooxy-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2,6-dihydro-4H- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester.
In an embodiment of the present invention, the oxazolidinone prodrugs of Formula (II) include compounds selected from the group consisting of:
Cpd Name
4a Piperazin-1-yl-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2,6-dihydro-4H- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester, Cpd Name
4b Piperazin-1-yl-acetic acid 1 -(acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2, 6-dihydro-
4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-ethyl ester,
5 Dimethylamino-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2, 6-dihydro-4H- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
8 (4-Methyl-piperazin-l-yl)-acetic acid (acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
10 Methylamino-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4/f- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester, and
21a Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid ethoxy-hydroxy- phosphoryloxymethyl ester.
Compound 1 is possessed of antimicrobial properties as described in United States Patent 6,413,981, which is incorporated herein by reference.
With reference to United States Patent 6,413,981, compounds of this invention include the following:
Figure imgf000011_0001
Cpd 5
Figure imgf000012_0001
CpdlO
Figure imgf000012_0002
Cpd 18a
Figure imgf000013_0001
Cpd 24 Abbreviations used in the instant specification and their meanings are as follows:
Abbreviation Meaning
Boc tert-butoxycarbonyl
DCM dichloromethane
DMF dimethylformamide
DMSO dimethyl sulfoxide
Eq or equiv equivalent
EtOAc ethyl acetate g grams h hours
HPLC high performance liquid chromatography
M molar
MeOH methanol mg milligram min minutes rnL milliliter
HCl hydrochloric acid
MS mass spectrometry
MPLC medium pressure liquid chromatography
N normal Abbreviation Meaning
NaHCO3 sodium bicarbonate
NaHMDS sodium hexamethyldisilazide
Na2SO4 sodium sulfate
NH4Cl ammonium chloride
NMR nuclear magnetic resonance psi pounds per square inch (gas) rt or RT room temperature
TFA trifluoroacetic acid
THF tetrahydrofuran
The compounds of Formula (II) may be prepared from Compound 1, the synthesis of Compound 1 is described in US 6,413,981. Outlined in Schemes 1 through 5 are representative procedures to prepare the compounds of the instant invention.
Scheme 1
Figure imgf000014_0001
Scheme 1 illustrates the method of synthesis of the chloroalkoxycarbonyl precursors (2) to the compounds of the invention. Compound 1 is reacted with a chloroalkyl chloro formate derivative in the presence of a base. Preferred bases include sodium hexamethyldisilazide, potassium hexamethyldisilazide, lithium diisopropylamide (LDA), lithium tetramethylpiperidide, l,8-diazabicyclo[5.4.0]undec-7-ene (DBU), tetramethylguanidine, and others. The reaction is preferably run for between 30 min to 24 h in an inert solvent such as THF, dioxane, 1 ,2-dimethoxyethane (DME), or DMF at a temperature ranging from -78 0C to 80 0C. Scheme 2
Figure imgf000015_0001
2. deprotection ° (if protecting
Figure imgf000015_0002
group present
Figure imgf000015_0003
in X)
Scheme 2 depicts the conversion of the chloroalkoxycarbonyl derivatives (2) from Scheme 1 to a variety of compounds of the instant invention, including the substituted acyloxymethoxycarbonyl derivatives of Formula (III), wherein R1, X and n are as defined above. As shown in Scheme 2, derivative 2 is reacted with an alkali metal (preferably cesium) salt of an appropriately substituted carboxylic acid derivative. The reaction is optionally performed in the presence of an iodide salt, such as potassium iodide or sodium iodide, in a suitable solvent such as DMF, acetonitrile, or DMSO. The reaction is performed at a temperature ranging from 0 0C to 100 0C for from 2 h to 48 h. If a protecting group is present in the compound of Formula (III), it may optionally be removed by methods known to those skilled in the art to provide compounds of Formula (III) in which the protecting group has been replaced by a hydrogen atom. Amine protecting groups include, but are not limited to, tert-butyloxycarbonyl (Boc), which may be removed under acidic conditions, for example by treatment with trifluoroacetic acid in DCM or HCl in ethyl ether, and carbobenzyloxy (Cbz), which may be removed by hydrogeno lysis. Phosphate protecting groups include, but are not limited to, tert-butyi (1Bu), which may be removed under acidic conditions, such as by treatment with trifluoroacetic acid in DCM or HCl in ethyl ether, and benzyl (Bn), which may be removed by hydrogenolysis.
Scheme 3
Figure imgf000016_0001
2. deprotection
(if protecting
Figure imgf000016_0003
group present
Figure imgf000016_0002
in Y)
Scheme 3 illustrates the synthesis of compounds of Formula IV from derivative Compound 2. The process is similar to the one described in Scheme 2. Derivative Compound 2 is reacted with an alkali metal (preferably cesium) salt of a suitably substituted benzoic acid derivative to provide compounds of Formula (IV). Typically the reaction is conducted in a suitable solvent, such as DMF, acetonitrile, or DMSO at a temperature ranging from 0 0C to 100 0C for from 2 h to 48 h, optionally in the presence of an iodide salt, such as potassium iodide or sodium iodide. If a protecting group is present in the compounds of Formula (IV), it may optionally be removed by methods known to those skilled in the art to provide compounds of Formula (IV) in which the protecting group has been replaced by a hydrogen atom. Phosphate protecting groups include, but are not limited to, tert-butyi (1Bu), which may be removed under acidic conditions, such as by treatment with trifluoroacetic acid in DCM or HCl in ethyl ether, and benzyl (Bn), which may be removed by hydrogeno lysis .
Scheme 4
Figure imgf000016_0004
Scheme 4 illustrates the synthesis of phosphate ester compounds of Formula (V) from derivative Compound 2. As shown in Scheme 4, derivative Compound 2 is reacted with a suitably protected salt of a phosphoric acid diester derivative. The reaction is optionally performed in the presence of an iodide salt, such as potassium iodide or sodium iodide, in an appropriate solvent, such as DMF, THF, or DMSO. The reaction is preferably performed at a temperature ranging from 0 0C to 100 0C for from 2 h to 96 h, followed by removal of the PG1 protecting group to provide compounds of Formula (V) wherein R is lower alkyl. Preferred phosphate salts are those in which Z+ is tetraalkylammonium, which may be prepared by exchange of the t-butylamine salt with a tetraalkylammonium hydroxide derivative. Phosphate protecting groups include, but are not limited to, tert-butyi (1Bu), which may be removed under acidic conditions, such as by treatment with trifluoroacetic acid in DCM or HCl in ethyl ether, and benzyl (Bn), which may be removed by hydrogeno lysis.
Scheme 5
Figure imgf000017_0001
Scheme 5 illustrates the synthesis of phosphate compounds of Formula (VI) from derivative Compound 2. As shown, derivative Compound 2 is reacted with a suitably protected salt of a phosphoric acid diester derivative to produce compounds of Formula (VI). The reaction is optionally performed in the presence of an iodide salt, such as potassium iodide or sodium iodide, in an appropriate solvent, such as DMF, THF, or DMSO, at a temperature ranging from 0 0C to 100 0C for from 2 h to 96 h, followed by removal of the PG1 protecting groups. Preferred phosphate salts are those in which Z+ is tetraalkylammonium. Phosphate protecting groups include, but are not limited to, tert- butyl (1Bu), which may be removed under acidic conditions, such as by treatment with trifluoroacetic acid in DCM or HCl in ethyl ether, and benzyl (Bn), which may be removed by hydrogenolysis.
The following Examples illustrate preferred methods of synthesis for several compounds of Formula (I) and Formula (II). Example 1
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H- pyrrolo[3,4c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamic acid chloromethyl ester (2a)
Figure imgf000018_0001
1 2a, R1 = H 2b, R1 = Me
To a suspension of 1 (6.0 g, 16.1 mmol) in anhydrous THF (150 rnL) was added NaHMDS (20.9 mL, 20.9 mmol, 1.0 M solution in THF), and the reaction mixture was stirred at rt for 45 min under a nitrogen atmosphere. Chloromethyl chloro formate (1.84 mL, 20.9 mmol) was added and stirring was continued for an additional 45 min. The reaction mixture was quenched with saturated aqueous NH4Cl, and extracted three times with ethyl acetate. The combined organic extracts were dried with Na2SO4 and concentrated in vacuo. Purification by MPLC (SiO2, 1-10% gradient elution, MeOH : CH2Cl2) gave 4.29 g (58%) of the title compound as an off white solid. 1H NMR (400 MHz, DMSO-J6): δ 7.54 (s, IH), 7.43 (dd, IH), 7.14 (dd, IH), 6.87 (dd, IH), 6.03-5.98 (m, 2H), 4.81-4.74 (m, IH), 4.48-4.46 (m, 4H), 4.15 (dd, IH), 4.11 (dd, IH), 3.91 (dd, IH), 3.85 (s, 3H), 3.78 (dd, IH), and 2.49 (s, 3H). MS 466 (M + I)+
Example 2
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4/f-pyrrolo[3,4- c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid 1 - chloro-ethyl ester (2b)
To a suspension of 1 (500 mg, 1.34 mmol) in anhydrous THF (8 mL) was added NaHMDS (1.75 mL, 1.75 mmol, 1.0 M solution in THF), and the reaction mixture was stirred at rt for 1 h under a nitrogen atmosphere. Chloroethyl chloroformate (0.18 mL, 1.74 mmol) was added and stirring was continued for an additional 3 h. The reaction mixture was quenched with saturated aqueous NH4Cl, and extracted three times with ethyl acetate. The combined organic extracts were washed with saturated aqueous NH4Cl, dried with Na2SO4, and concentrated in vacuo. Purification by MPLC (silica, 1-10% gradient elution, MeOH : CH2Cl2) gave 338 mg (52%) of the title compound as a mixture of diastereomers. 1H NMR (400 MHz, DMSO-J6); δ 7.53 (s, IH), 7.41 (dd, IH), 7.17-7.13 (m, IH), 6.90- 6.85 (m, IH), 6.66-6.60 (m, IH), 4.82-4.72 (m, IH), 4.48-4.46 (m, 4H), 4.19-4.07 (m, 2H), 3.96-3.86 (m, IH), 3.84 (s, 3H), 3.80-3.75 (m, IH), 2.48 (s, 3H), and 1.84-1.82 (m, 3H). MS 480 (M + I)+
General Procedure A Preparation of cesium salts from the corresponding amino acids:
To a solution of amino acid (23.7 mmol) in MeOH (20 mL) and water (10 mL) was added cesium carbonate (11.8 mmol) in small portions. The resulting solution was stirred at rt for 5 min, concentrated in vacuo to remove MeOH, frozen, and then lyophilized to give a white powder. Toluene was added to this powder, and the suspension was concentrated in vacuo, and the resulting white powder was dried in a vacuum oven at 50 0C overnight to give a quantitative yield of cesium salt as a white powder.
Example 3
4-[(Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4- c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)- methoxycarbonylmethyl]-piperazine-l-carboxylic acid tert-butyl ester (3a)
Figure imgf000020_0001
2b, R1 = Me 3b, R1 = Me
Figure imgf000020_0002
4a, R1 = H 4b, R1 = Me
To a solution of 2a (1.41 g, 3.04 mmol) in DMF was added the cesium salt of 4- carboxymethyl-piperazine-1-carboxylic acid tert-butyl ester (1.71 g, 4.56 mol, prepared from 4-carboxymethyl-piperazine-l-carboxylic acid tert-butyl ester following general procedure A) and the resulting suspension was stirred at rt for 20 h and at 40 0C for 2 h. The reaction mixture was then filtered and purified directly by HPLC (C- 18 column, 30- 90% gradient elution, MeCN : H2O), and fractions containing product were lyophilized to give 0.670 g, (33%) of the title compound as a fluffy white solid. 1H NMR (400 MHz, DMSO-J6): δ 7.53 (s, IH), 7.42 (dd, IH), 7.15 (dd, IH), 6.87 (dd, IH), 5.83 (s, 2H), 4.78- 4.70 (m, IH), 4.48-4.46 (m, 4H), 4.12-4.06 (m, 2H), 3.89 (dd, IH), 3.84 (s, 3H), 3.76 (dd, IH), 3.38 (s, 2H), 3.30-3.28 (m, 4H), 2.47-2.45 (m, 4H), 2.45 (s, 3H), and 1.38 (s, 9H). MS 674 (M + I)+ Example 4
Piperazin- 1 -yl-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl}-carbamoyloxy)-methyl ester (4a) To a solution of 3a (1.25 g, 1.85 mmol) in dichloromethane (18 mL) was added dropwise a solution of IN HCl in diethyl ether (18.5 mL, 18.5 mmol), and the reaction mixture was stirred under nitrogen at rt for 2 h. The reaction mixture was concentrated in vacuo and purified directly by HPLC (C- 18 column, 5-55% gradient elution, MeCN : H2O), to give 0.530 g (53%) of the title compound. 1H NMR (400 MHz, DMSO-J6): δ 8.77 (br s, IH) 7.54 (s, IH), 7.42 (dd, IH), 7.15 (dd, IH), 6.87 (dd, IH), 5.86-5.83 (m, 2H), 4.78-4.72 (m, IH), 4.48-4.46 (m, 4H), 4.13-4.06 (m, 2H), 3.90 (dd, IH), 3.85 (s, 3H), 3.77 (dd, IH), 3.49 (s, 2H), 3.07-3.04 (m, 4H), 2.78-2.76 (m, 4H), and 2.46 (s, 3H). MS 574 (M
+ I)+
Example 5 4-[ 1 -(Acetyl- {(R)-3-[3-fiuoro-4-(2-methyl-2,6-dihydro-4/f- pyrrolo[3,4c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-ethoxycarbonylmethyl]-piperazine- 1 -carboxylic acid tert-butyl ester (3b)
To a solution of 2b (600 mg, 1.26 mmol) in DMF (10 mL) was added the cesium salt of 4-carboxymethyl-piperazine-l -carboxylic acid tert-butyl ester (0.950 g, 2.54 mmol, prepared from 4-carboxymethyl-piperazine-l -carboxylic acid tert-butyl ester following general procedure A) and the resulting suspension was stirred at rt overnight under an atmosphere of nitrogen. The reaction mixture was then filtered and purified directly by HPLC (C- 18 column, 30-90% gradient elution, MeCN : H2O), and fractions containing product were lyophilized to give 95 mg (11%) of the title compound as a mixture of diastereomers. 1H NMR (400 MHz, DMSO-J6): δ 7.53 (s, IH), 7.44-7.39 (m, IH), 7.17- 7.14 (m, IH), 6.90-6.78 (m, 2H), 4.78-4.70 (m, IH), 4.48-4.46 (m, 4H), 4.14-4.02 (m, 2H), 3.93-3.87 (m, IH), 3.84 (s, 3H), 3.78-3.74 (m, IH), 3.32 (s, 2H), 3.32-3.25 (m, 4H), 2.47- 2.42 (m, 7H), 1.52-1.51 (m, 3H), and 1.38-1.37 (m, 9H). MS 688 (M + I)+ Example 6
Piperazin- 1 -yl-acetic acid 1 -(acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl}-carbamoyloxy)-ethyl ester (4b) To a solution of 3b (170 mg, 0.25 mmol) in dichloromethane (18 mL) was added dropwise a solution of IN HCl in diethyl ether (18.5 mL, 18.5 mmol), and the reaction mixture was stirred under nitrogen at rt for 2 h. The reaction mixture was concentrated in vacuo and purified directly by HPLC (C- 18 column, 10-55% gradient elution, MeCN : H2O), to give 70 mg (48%) of the title compound. 1U NMR (400 MHz, DMSO-J6): δ 8.60 (br s, IH) 7.54 (s, IH), 7.45-7.40 (m, IH), 7.17-7.14 (m, IH), 6.90-6.79 (m, 2H), 4.77-4.71 (m, IH), 4.48-4.46 (m, 4H), 4.14-4.03 (m, 2H), 3.94-3.89 (m, IH), 3.85 (s, 3H), 3.79-3.75 (m, IH), 3.46-3.42 (m, 2H), 3.09-3.05 (m, 4H), 2.78-2.73 (m, 4H), 2.45-2.44 (m, 3H), and 1.53-1.51 (m, 3H). MS 588 (M + I)+
Example 7 Dimethylamino-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2, 6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl}-carbamoyloxy)-methyl ester (5)
Figure imgf000022_0001
2a 5
To a solution of 2a (379 g, 0.81 mmol) in DMF (1.6 mL) was added the cesium salt of JV,jV-dimethyl glycine (192 mg, 0.81 mmol, prepared from JV,iV-dimethyl glycine following general procedure A) and the resulting suspension was stirred at rt for 24 h. The reaction mixture was filtered, purified directly by HPLC (C- 18 column, 30-100% gradient elution, MeCNiH2O), and fractions containing product were lyophilized to give 99 mg (23%) of the title compound as a white powder. 1H NMR (400 MHz, DMSO-J6): δ 7.53 (s, IH), 7.43 (dd, IH), 7.16 (dd, IH), 6.87 (dd, IH), 5.70-5.65 (m, 2H), 4.85-4.78 (m, IH), 4.48-4.46 (m, 4H), 4.22 (dd, IH), 4.13 (dd, IH), 4.00 (dd, IH), 3.85 (s, 3H), 3.79 (dd, IH), 3.72 (s, 2H), 3.20 (s, 3H), 3.19 (s, 3H), and 2.50 (s, 3H). MS 533 (M + I)+ Example 8
Morpholin-4-yl-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl}-carbamoyloxy)-methyl ester (6)
Figure imgf000023_0001
2a 6
To a solution of 2a (330 mg, 0.71 mmol) in DMF (3.0) mL) was added the cesium salt of morpholine-jV-acetic acid (235 mg, 0.85 mmol, prepared from morpholine-iV-acetic acid following general procedure A) and the resulting suspension was stirred at rt overnight and at 40 0C for an additional 6 h. The reaction mixture was then filtered and purified directly by HPLC (C-18 column, 30-90% gradient elution, MeCNiH2O), and fractions containing product were lyophilized to give 45 mg, (11%) of the title compound as a white powder. 1H NMR (400 MHz, DMSO-J6): δ 7.53 (s, IH), 7.42 (dd, IH), 7.15 (dd, IH), 6.87 (dd, IH), 5.84 (s, 2H), 4.78-4.71 (m, IH), 4.48-4.46 (m, 4H), 4.13-4.07 (m, 2H), 3.89 (dd, IH), 3.85 (s, 3H), 3.76 (dd, IH), 3.56-3.54 (m, 4H), 3.34 (s, 2H), and 2.45 (s, 3H). MS 575 (M + I)+
Example 9
1 -Methyl-pyrrolidine-2-carboxylic acid (acetyl- {(R)-3-[3-fluoro-4-(2- methyl-2,6-dihydro-4/f-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (7)
Figure imgf000023_0002
2a 7
To a solution of 2a (300 mg, 0.65 mmol) in DMF (2.5) mL was added the cesium salt of JV-methyl-L-proline (335 mg, 1.29 mmol, prepared from JV-methyl-L-proline following general procedure A) and the resulting suspension was stirred overnight at rt. The reaction mixture was filtered, purified directly by HPLC (C- 18 column, 30-50% gradient elution, MeCNiH2O), and fractions containing product were lyophilized to give 90 mg (25%) of the title compound as mixture of diastereomers (dr 1 : 1.80). 1H NMR (400 MHz, DMSO-J6): δ 7.53 (s, IH), 7.46-7.40 (m, IH), 7.17-7.14 (m, IH), 6.90-6.85 (m, IH), 6.11-6.04 (m, IH), 5.42-5.29 (m, IH), 4.87-4.79 (m, IH), 4.48-4.46 (m, 4H), 4.27-3.90 (m, 4H), 3.84 (s, 3H), 3.78 (dd, IH), 3.72-3.35 (m, 2H), 3.23 and 3.08 (two s, 3H), and 2.33- 1.91 (m, 4H). MS 559 (M + I)+
Example 10
(4-Methyl-piperazin-l-yl)-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2- methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (8)
Figure imgf000024_0001
2a 8
To a solution of 2a (300 mg, 0.65 mmol) in DMF (3.0 mL) was added the cesium salt of (4-methyl-piperazin-l-yl)-acetic acid (379 mg, 1.30 mol, prepared from (4-methyl- piperazin-l-yl)-acetic acid following general procedure A) and the resulting suspension was stirred at rt for 6 h. The reaction mixture was filtered, purified directly by HPLC (C- 18 column, 30-80% gradient elution, MeCNiH2O), and fractions containing product were lyophilized to give 80 mg, (21%) of the title compound as a white powder. 1H NMR (400 MHz, DMSO-J6): δ 7.53 (s, IH), 7.42 (dd, IH), 7.15 (dd, IH), 6.87 (dd, IH), 5.83 (s, 2H), 4.78-4.71 (m, IH), 4.48-4.46 (m, 4H), 4.13-4.07 (m, 2H), 3.89 (dd, IH), 3.86 (s, 3H), 3.76 (dd, IH), 3.32 (s, 2H), 2.45 (s, 3H), 2.32-2.24 (m, 4H), and 2.12 (s, 3H). MS 588 (M + I)+
Example 11
(tert-Butoxycarbonyl-methyl-amino)-acetic acid (acetyl- {(R)-3-[3- fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)- phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamoyloxy)-methyl ester (9)
Figure imgf000025_0001
10
To a solution of 2a (200 mg, 0.43 mmol) in DMF (2 rnL) was added the cesium salt oϊN-Boc sarcosine (276 mg, 0.86 mmol, prepared from N-Boc sarcosine following general procedure A) and the reaction mixture was stirred overnight at rt. The reaction mixture was filtered, purified directly by HPLC (C- 18 column, 30-100% gradient elution, MeCNiH2O), and fractions containing product were lyophilized to give 82 mg (31%) of the title compound as a fluffy white solid. 1H NMR (400 MHz,
Figure imgf000025_0002
observed as a mixture of rotomers. δ 7.53 (s, IH), 7.42 (dd, IH), 7.15 (dd, IH), 6.87 (dd, IH), 5.88-5.86 (m, 2H), 4.79-4.71 (m, IH), 4.48-4.46 (m, 4H), 4.15-4.08 (m, 2H), 4.06 (br s, 2H), 3.92-3.86 (m, IH), 3.85 (s, 3H), 3.78 (dd, IH), 2.86 and 2.82 (two s, 3 H), 2.46 (s, 3H), 1.38 and 1.32 (two s, 9 H). MS 619 (M + I)+
Example 12
Methylamino-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl}-carbamoyloxy)-methyl ester (10) To a solution of 9 (50 mg, 0.08 mmol) in CH2Cl2 (2 mL) under nitrogen was added
IN HCl in Et2O (2.0 mL, 2.0 mmol). The reaction mixture was stirred at rt for 2 h, concentrated in vacuo, and purified directly by HPLC (C- 18 column, 30-80% gradient elution, MeCN:H2O with 0.1% TFA). Fractions containing product were lyophilized to give 15 mg (36%) of the title compound as the trifluoroacetate salt. 1H NMR (400 MHz, DMSO-J6): δ 9.07 (br s, IH), 7.54 (s, IH), 7.43 (dd, IH), 7.16 (dd, IH), 6.87 (dd, IH), 5.96-5.92 (m, 2H), 4.80-4.74 (m, IH), 4.48-4.46 (m, 4H), 4.15-4.09 (m, 4H), 3.91 (dd, IH), 3.85 (s, 3H), 3.76 (dd, IH), 2.62 (s, 3H), 2.47 (s, 3H). MS 519 (M + I)+
Example 13
(S)-Pyrrolidine-l,2-dicarboxylic acid 2-[(acetyl-{(R)-3-[3-fiuoro-4-(2- methyl-2,6-dihydro-4/f-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl] ester l-tert-buty\ ester
(H)
Figure imgf000026_0001
12
To a solution of 2a (300 mg, 0.65 mmol) in DMF (2.5 mL) was added the cesium salt of JV-i?oc -L-proline (291 mg, 0.84 mmol, prepared from Λ/-i?oc-L-proline following general procedure A) and the reaction mixture was stirred overnight at rt. The reaction mixture was filtered, purified directly by HPLC (C- 18 column, 30-90% gradient elution, MeCNiH2O), and fractions containing product were lyophilized to give 243 mg (59%) of the title compound as a fluffy white solid. 1H NMR (400 MHz, CDCl3): δ 7.39-7.34 (m, IH), 7.14 (s, IH), 7.11-7.06 (m, IH), 6.71-6.66 (m, IH), 5.91 (s, 2H), 4.85-4.76 (m, IH), 4.57-4.56 (m, 4H), 4.33-4.17 (m, 2H), 4.09-3.98 (m, 2H), 3.93 (s, 3H), 3.70-3.64 (m, IH), 3.58-3.37 (m, 2H), 2.56 (s, 3H), 2.33-2.20 (m, IH), 2.05-1.86 (m, 3H), 1.42 and 1.40 (two s, 9H). MS 645 (M + I)+ Prophetic Example 14
(S)-Pyrrolidine-2-carboxylic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-
2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-
5-ylmethyl}-carbamoyloxy)-methyl ester (12) To a solution of 11 (1 equiv) in dichloromethane at rt under nitrogen is added TFA
(5 equiv) dropwise. The reaction mixture is stirred at rt for 2 h, concentrated in vacuo, purified directly by HPLC (C-18 column, 0-100% gradient elution, MeCNiH2O with 0.1% TFA), and fractions containing product are lyophilized to give the title compound. Theoretical MS 545 (M + I)+ Example 15
4-(Bis-benzyloxy-phosphoryloxymethyl)-benzoic acid (acetyl- {(R)-3-
[3-fluoro-4-(2-methyl-2,6-dihydro-4/f-pyrrolo[3,4-c]pyrazol-5-yl)- phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamoyloxy)-methyl ester (13)
Figure imgf000027_0001
14 To a solution of 4-[[[bis(phenylmethoxy)phosphinyl]oxy]methyl]-benzoic acid (69 mg, 0.17 mmol, prepared according to the procedure described in Zhu, Z.; Chen, H.; Goel, O. P.; Chan, O.H.; Stilgenbauer, L. A.; Stewart, B. H. BioorgMed. Chem. Lett. 2000, 10, 1121) in DMF (0.6 mL) was added cesium carbonate (22 mg, 0.06 mmol) and the reaction mixture was stirred at rt for 1 h. To this mixture was added 2a and stirring was continued overnight. The crude reaction mixture was filtered, purified directly by HPLC (C- 18 column, 30-100% gradient elution, MeCNiH2O), and fractions containing product were lyophilized to give 38 mg (35%) of the title compound. 1H NMR (400 MHz, DMSO-J6): δ 8.00 (d, 2H), 7.52 (s, IH), 7.50 (d, 2H), 7.38-7.33 (m, 11 H), 7.12 (dd, IH), 6.83 (dd, IH), 6.09-6.06 (m, 2H), 5.13 (d, 2H), 5.05 (d, 4H), 4.80-4.73 (m, IH), 4.47-4.45 (m, 4H), 4.15-4.06 (m, 2H), 3.92 (dd, IH), 3.84 (s, 3H), 3.78 (dd, IH), 2.47 (s, 3H). MS 842 (M +
I)+
Prophetic Example 16
4-Phosphonooxymethyl-benzoic acid (acetyl- {(R)-3-[3-fluoro-4-(2 - methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (14)
A suspension of 13 (1 equiv) and 10% Pd/C (1 weight equiv of 13) in methanol is hydrogenated in a Parr shaker at 30 psi for 6 h. The reaction mixture is filtered, concentrated in vacuo, purified directly by HPLC (C-18 column, 0-100% gradient elution, MeCNiH2O), and fractions containing product are lyophilized to give the title compound. Theoretical MS 662 (M + I)+
Example 17
4-(Bis-benzyloxy-phosphoryloxy)-benzoic acid (acetyl- {(R)-3-[3- fluoro-4-(2-methyl-2,6-dihydro-4/f-pyrrolo[3,4-c]pyrazol-5-yl)- phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamoyloxy)-methyl ester (15)
Figure imgf000028_0001
To a solution of 2a (232 mg, 0.50 mmol) in DMF (1.5 mL) was added the cesium salt of 4-(bis-benzyloxy-phosphoryloxy)-benzoic acid (397 mg, 0.75 mmol; 4-(bis- benzyloxy-phosphoryloxy)-benzoic acid was prepared following the procedure described in WO 2001027106. The cesium salt of 4-(bis-benzyloxy-phosphoryloxy)-benzoic acid was prepared using general procedure A). The reaction mixture was stirred overnight at rt, filtered, and purified directly by HPLC (C- 18 column, 30-100% gradient elution, MeCNiH2O). Fractions containing product were lyophilized to give 85 mg (21%) of the title compound as a fluffy white solid. 1U NMR (400 MHz, DMSO-J6): δ 8.03 (d, 2H), 7.52 (s, IH), 7.42-7.33 (m, 13H), 7.11 (dd, IH), 6.83 (dd, IH), 6.07-6.04 (m, 2H), 5.18 (d, 4H), 4.80-4.73 (m, IH), 4.47-4.45 (m, 4H), 4.15-4.07 (m, 2H), 3.92 (dd, IH), 3.84 (s, 3H), 3.76 (dd, IH), 2.47 (s, 3H). MS 828 (M + I)+
Prophetic Example 18
4-Phosphonooxy-benzoic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl}-carbamoyloxy)-methyl ester (16)
A suspension of 15 (1 equiv) and 10% Pd/C (1 weight equiv of 15) in 1,4- cyclohexadiene and THF is stirred at rt for 6 h. The reaction mixture is filtered, concentrated in vacuo, purified directly by HPLC (C-18 column, 0-100% gradient elution, MeCNiH2O), and fractions containing product are lyophilized to give the title compound. Theoretical MS 646 (M + I)+
Example 19
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4/f-pyrrolo[3,4- c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamic acid di-tert-butoxy-phosphoryloxymethyl ester (17a)
Figure imgf000029_0001
18a, R1 = H
18b, R1 = Me To a solution of 2a (1.545 g, 3.33 mmol) in THF (25 niL) was added sodium iodide (549 mg, 3.66 mmol) and the tetrabutylammonium salt of di-te/t-butylphosphate (1.545 g, 3.42 mmol). The reaction mixture was heated at 65 0C for 24 h, concentrated in vacuo, dissolved in DMSO, filtered, and purified directly by HPLC (C- 18 column, 30-100% gradient elution, MeCNiH2O). Fractions containing product were lyophilized to give 1.07 g (50%) of the title compound. 1H NMR (400 MHz, DMSO-J6): δ 7.53 (s, IH), 7.42 (dd, IH), 7.16 (dd, IH), 6.87 (dd, IH), 5.68 (dd, IH), 5.60 (dd, IH), 4.85-4.78 (m, IH), 4.48- 4.46 (m, 4H), 4.19-4.08 (m, 2H), 3.90 (dd, IH), 3.84 (s, 3H), 3.79 (dd, IH), 2.49 (s, 3H), 1.42 (s, 18H). MS 1301 (2M + 23)+ Example 20
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4/f-pyrrolo[3,4- c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid 1 -
(di-teτt-butoxy-phosphoryloxy)-ethyl ester (17b)
To a solution of 2b (75 mg, 0.16 mmol) in THF (1.5 mL) was added sodium iodide (66 mg, 0.44 mmol) and the tetrabutylammonium salt of di-te/t-butylphosphate (200 mg, 0.04 mmol). The reaction mixture was heated at 65 0C for 48 h, concentrated in vacuo, dissolved in DMSO, filtered, and purified directly by HPLC (C- 18 column, 30-100% gradient elution, MeCNiH2O). Fractions containing product were lyophilized to give 20 mg (20%) of the title compound as a 1 : 1 mixture of diastereomers. 1H NMR (400 MHz, DMSO-J6): δ 7.53 (s, IH), 7.44-7.39 (m, IH), 7.17-7.14 (m, IH), 6.90-6.85 (m, IH), 6.45- 6.38 (m, IH), 4.85-4.75 (m, IH), 4.48-4.46 (m, 4H), 4.25-4.08 (m, 2H), 3.95-3.77 (m, 2H), 3.85 (s, 3H), 2.47-2.48 (m, 3H), 1.56-1.54 (m, 3H), 1.41-1.40 (m, 18H). MS 654 (M + I)+
Example 21
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4/f-pyrrolo[3,4- c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid phosphonooxymethyl ester (18a)
To a solution of 17a (500 mg, 0.78 mmol) in dichloromethane (2.5 mL) under an atmosphere of nitrogen was added a solution of IN HCl in diethyl ether (2.34 mL, 2.34 mmol) and the reaction mixture was stirred at rt for 3 h. The reaction mixture was concentrated in vacuo, purified directly by HPLC (C-18 column, 10-100% gradient elution, MeCNiH2O), and fractions containing product were lyophilized to give 290 mg (70%) of the title compound. 1H NMR (400 MHz, DMSO-J6): δ 7.53 (s, IH), 7.42 (dd, IH), 7.16 (dd, IH), 6.87 (dd, IH), 5.65 (dd, IH), 5.58 (dd, IH), 4.87-4.80 (m, IH), 4.48- 4.46 (m, 4H), 4.20 (dd, IH), 4.09 (dd, IH), 3.87 (dd, IH), 3.84 (s, 3H), 3.78 (dd, IH), and 2.49 (s, 3H). MS 528 (M + I)+ Prophetic Example 22
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4/f-pyrrolo[3,4- c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid 1 - phosphonooxy-ethyl ester (18b)
To a solution of 17b (1 equiv) in dichloromethane is added TFA (3 equiv) and the reaction mixture is stirred at rt for 3 h. The reaction mixture is concentrated in vacuo, and purified directly by HPLC (C-18 column, 10-100% gradient elution, MeCNiH2O) to give the title compound. Theoretical MS 542 (M + I)+
Example 23
Tetrabutyl ammonium salt of Phosphoric acid benzyl ester ethyl ester (19)
Figure imgf000031_0001
The first step in this reaction sequence was carried out according to a procedure described in Gray, M. D. M.; Smith, D. J. H. Tetrahedron. Lett. 1980, 21, 859. A solution of phosphoric acid dibenzyl ester ethyl ester (5.22 g, 17.05 mmol) in te/t-butylamine (10 mL) was heated at 92 0C (oil bath temperature) in a sealed tube for 8 h. Upon cooling to rt a white waxy solid formed. To this solid was added tetrabutylammonium hydroxide (11.37 mL, 17.05 mmol) and the resulting homogenous solution was extracted three times with diethyl ether. The aqueous layer was concentrated in vacuo and dried under a vacuum overnight to give 7.53 g (96%) of a pale brown oil, which was used in the next step without further purification. 1H NMR (400 MHz, DMSO-J6): δ 7.33-7.20 (m, 5H), 4.63 (d, 2H), 3.65-3.58 (m, 2H), 3.19-3.15 (m, 8H), 1.60-1.53 (m, 8H), 1.35-1.26 (m, 8H), 1.05 (t, 3H), and 0.93 (t, 12H). Example 24
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4- c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamic acid benzyloxy-ethoxy-phosphoryloxymethyl ester (20a)
Figure imgf000032_0001
2b, R1 = Me 20b, R1 = Me
To a solution 2a (3.96 g, 8.52 mmol) in DMF (12 mL) was added phosphate derivative 19 (7.53 g, 17.05 mmol). The reaction mixture was stirred at rt for 48 h, filtered, and purified directly by HPLC (C-18 column, 50-80% gradient elution, MeCNiH2O) to give 1.20 g (22%) of the title compound as a fluffy white powder. 1H NMR (400 MHz, DMSO-J6): δ 7.54 (s, IH), 7.44-7.34 (m, 6H), 7.16-7.13 (m, IH), 6.89-6.84 (m, IH), 5.77- 5.66 (m, 2H), 5.08 (d, 2H), 4.81-4.73 (m, IH), 4.48-4.46 (m, 4H), 4.14-4.04 (m, 4H), 3.87- 3.82 (m, 4H), 3.77-3.73 (m, IH), 2.44 and 2.43 (two s, 3H), 1.22 (dt, 3H). MS 646 (M +
I)+
Prophetic Example 25
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4/f-pyrrolo[3,4- c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid 1 - (benzyloxy-ethoxy-phosphoryloxy)-ethyl ester (20b)
To a solution 2b (1 equiv.) in DMF is added phosphate derivative 19 (2 equiv.). The reaction mixture is stirred at rt for 48 h, filtered, and purified directly by HPLC (C- 18 column, 50-80% gradient elution, MeCNiH2O) to give the title compound. Theoretical MS 660 (M + I)+ Example 26
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4- c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamic acid ethoxy-hydroxy-phosphoryloxymethyl ester (21a)
Figure imgf000033_0001
A solution of 20a (1.20 g, 1.86 mmol) in methanol (40 mL) was passed through an "H-cube" hydrogenator equipped with a 10% Pd on carbon cartridge under 30 bar of hydrogen at a flow rate of 1 mL/min. The reaction mixture was concentrated in vacuo and purified directly by HPLC (C-18 column, 5-55% gradient elution, MeCN :H2O). Fractions containing product were lyophilized to give 555 mg (54%) of the title compound as a fluffy white solid. 1H NMR (400 MHz, DMSO-J6): δ 7.54 (s, IH), 7.43 (dd, IH), 7.17 (dd, IH), 6.87 (dd, IH), 5.70-5.57 (m, 2H), 4.86-4.79 (m, IH), 4.48-4.46 (m, 4H), 4.18 (dd, IH), 4.10 (t, IH), 3.99-3.91 (m, 2H), 3.88 (dd, IH), 3.85 (s, 3H), 3.79 (dd, IH), 2.49 (s, 3H), 1.20 (t, 3H). MS 556 (M + I)+ Prophetic Example 27
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4/f-pyrrolo[3,4- c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid 1 -
(ethoxy-hydroxy-phosphoryloxy)-ethyl ester (21b)
A solution of 20b (1 equiv.) in methanol is passed through an "H-cube" hydrogenator equipped with a 10% Pd on carbon cartridge under 30 bar of hydrogen at a flow rate of 1 mL/min. The reaction mixture is concentrated in vacuo and purified directly by HPLC (C- 18 column, 5-55% gradient elution, MeCN :H2O) to give the title compound. Theoretical MS 570 (M + I)+ Example 28 Cesium salt of (di-tert-butoxy-phosphoryloxy)-acetic acid (22)
Figure imgf000034_0001
Step 1 : To a solution of benzyl glycolate (2.0 mL, 14.1 mmol) and triethylamine (2.35 mL, 16.9 mmol) in dichloromethane (30 mL) at 0 0C was added dropwise methanesulfonyl chloride (1.20 mL, 15.1 mL). The reaction was stirred overnight, diluted with dichloromethane, washed with saturated aqueous NH4Cl, and then with saturated NaHCθ3, dried with Na2SO4, and concentrated in vacuo to give 2.50 g (73%) of methanesulfonyloxy-acetic acid benzyl ester which was used in the next step without further purification.
Step 2 :To a solution of methanesulfonyloxy-acetic acid benzyl ester (2.50 g, 10.24 mmol) in THF (20 mL) was added the tetrabutylammonium salt of di-te/t-butylphosphate (4.61 g, 10.24 mmol). The reaction was stirred overnight, concentrated, and purified directly by MPLC (SiO2, 10-30% gradient elution, Hexane : EtOAc) to give 1.42 g (39%) of (di-tert-butoxy-phosphoryloxy)-acetic acid benzyl ester. 1H NMR (400 MHz, CDCI3): δ 7.37-7.35 (m, 5H), 5.21 (s, 2H), 4.55 (d, 2H), and 1.48 (s, 18H). Step 3: (Di-tert-butoxy-phosphoryloxy)-acetic acid benzyl ester (700 mg, 1.96 mmol) was dissolved in MeOH (40 rnL) and passed through a "H-cube" hydrogenator with a 10% Pd on carbon cartridge under 40 psi of hydrogen at a flow rate of 1 mL/min. The reaction mixture was concentrated in vacuo to give 513 mg (98%) of (di-te/t-butoxy- phosphoryloxy)-acetic acid, which was used in the next step without further purification. 1H NMR (400 MHz, CDCl3): δ 4.53 (d, 2H), and 1.51 (s, 18H).
Step 4: To a solution of (di-tert-butoxy-phosphoryloxy)-acetic acid (480 mg, 1.79 mmol) in MeOH (4 mL) and water (2 mL) was added cesium carbonate (261 mg, 0.80 mmol) and the reaction was stirred at rt for 10 min. The resulting homogenous solution was concentrated in vacuo to give the title compound as a gummy solid.
Example 29
(Di-tert-butoxy-phosphoryloxy)-acetic acid (acetyl- {(R)-3-[3-fluoro-4-
(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (23) To a solution of 2a (579 mg, 1.24 mmol) in DMF (2.5 mL) was added 22 (1.49 g,
3.73 mmol) and the reaction mixture was stirred overnight at rt. The reaction mixture was filtered, purified directly by HPLC (C- 18 column, 30-100% gradient elution, MeCNiH2O), and fractions containing product were lyophilized to give 438 mg (51%) of the title compound as a fluffy white solid. 1U NMR (400 MHz, DMSO-J6): δ 7.53 (s, IH), 7.42 (dd, IH), 7.14 (dd, IH), 6.87 (dd, IH), 5.89 (s, 2H), 4.80-4.72 (m, IH), 4.60 (d, 2H), 4.48- 4.46 (m, 4H), 4.14-4.08 (m, 2H), 3.89 (dd, IH), 3.85 (s, 3H), 3.76 (dd, IH), 2.46 (s, 3H), and 1.41 (s, 18H). MS 698 (M + I)+
Example 30
Phosphonooxy-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl}-carbamoyloxy)-methyl ester (24)
To a solution of 23 (20 mg, 0.03 mmol) in dichloromethane (1 mL) under nitrogen was added dropwise a solution of IN HCl in diethyl ether (2.0 mL, 2.0 mmol). The reaction mixture was stirred for 1 h at rt, concentrated in vacuo, and purified directly by HPLC (C- 18 column, 10-70% gradient elution, MeCN:H2O with 0.1% TFA) to give 5 mg (25%) of the title compound. 1H NMR (400 MHz, DMSO-J6): δ 7.53 (s, IH), 7.42 (dd, IH), 7.15 (dd, IH), 6.87 (dd, IH), 5.88 (s, 2H), 4.79-4.72 (m, IH), 4.53 (d, 2H), 4.48-4.46 (m, 4H), 4.15-4.07 (m, 2H), 3.88 (dd, IH), 3.85 (s, 3H), 3.76 (dd, IH), and 2.46 (s, 3H). MS 586 (M + I)+
Prodrug Solubility
One mg of each compound was diluted with at least 100 μl of the designated buffer, vortexed vigorously for approximately 1 minute, and visually inspected. Sodium citrate (40 mM) was buffered to pH 4 and phosphate -buffered saline was buffered to pH 7. Solutions with no remaining particles were recorded with a solubility > to the starting concentration. Compound suspensions were further diluted in 0.1 mL increments followed by vortexing as above, until the prodrug was dissolved. The solubility of the prodrugs in the buffers tested is listed in Table 1. Solubilities of prodrugs ranged from 1.0 mg/ml to >10 mg/ml. The term "ND" means not determined.
Table 1
Solubility
Compound Sodium Citrate Saline
4a >10 mg/mL >10/mg/mL
4b >7.5 mg/mL ND
5 >10 mg/mL >10 mg/mL
6 2.5 mg/mL 1.0 mg/mL
8 >10 mg/mL >10/mg/mL
10 >10 mg/mL >10 mg/mL
18a >2 mg/mL >2 mg/mL
21a >10 mg/mL >10/mg/mL
24 >5 mg/mL ND The solubility of the active drug, Compound 1, was determined in a separate experiment in which an excess of the compound was added to pH 4 buffer. The mixture was shaken with a Burrell wrist action shaker at ambient temperature for 24 hours. Excess solute was removed by centrifugation, the supernatant was diluted with a suitable solvent, and the concentration of the compound was measured using HPLC. The solubility of Compound 1 at pH 4 was 0.007 mg/mL.
Evaluation of Prodrug Efficacy in a Mouse Systemic Lethal Infection Model Female Swiss Webster mice weighing between 20-25 g were infected intraperitoneally with approximately 5x105 colony forming units (CFU) S. aureus Smith in 7% mucin. One hour later, the animals were given prodrug or Compound 1 intravenously or orally in a dose volume of 0.1 mL/lOg body weight. Each group consisted of eight animals. The prodrugs were prepared immediately before dosing in 40 mM sodium citrate buffer, pH 4. Compound 1 was prepared in 20% HPβCD and warmed until dissolved (IV dosing) or in 0.5% methocel (PO dosing) as a suspension. The mice were observed over a three day period and ED50 values were calculated from the resulting % survival curves (Table 2). The term "ND" means not determined. The prodrug ED50 values were normalized to the content of Compound 1.
Table 2 ED50 in mg/kg (95% Fiducial Limits)
Compound IV PO a l 3.3 (2 .3 - 5.0) 3.5 (2 J - 4.5) a 4a 3.6 (2 .5-5 •1) 4.9 (3 .2-8 •1)
4b 4.2 (1 .2-7 •9) ND
5 4.8 (2 .5-8 .3) ND
8 5.3 (3 .2-9 •2) ND a 21a 2.9 (1 .9-4 •2) 4.4 (2. 6-8. .0) aThe ED50 was calculated from the results of two or more experiments conducted on separate days.
Pharmacokinetics of Prodrugs in Animal Models
Animals were weighed and given the prodrug intravenously (mice, rats, or dogs) or orally (mice). The prodrugs were prepared immediately before dosing in 40 mM sodium citrate buffer, pH 4. Compound 1 was prepared in 20% HPβCD and warmed until dissolved (IV dosing), or in 0.5% methocel as a suspension (PO dosing). At 0, 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours, blood was removed (via cardiac puncture in euthanized mice, via orbital sinus puncture in anesthetized rats, or via cephalic vein in conscious dogs) and 200 DL of the plasma supernatant was immediately frozen (-70 0C).
On the day of analysis, the samples were thawed on ice and 100 μL was diluted with 200 μL of acetonitrile. The samples were vortexed and then centrifuged at 3000 x g for 5 minutes to pellet the precipitated plasma proteins. The supernatant was analyzed by HPLC, or by LC-MS-MS. A standard curve was constructed by spiking a known quantity of Compound 1 into plasma and then performing serial dilutions in the range of 0.01 to 10 μg/mL. Pharmacokinetic (PK) parameters were calculated by WinNonlin Pro, version 3.1. The results indicate that, when normalized to the dose, PK parameters for
Compounds 4a and 21a were similar to the respective parameters for Compound 1 in all species tested (Table 3a-3d). This indicates that the prodrug form for Compounds 4a and 21a were rapidly converted in vivo to Compound 1, which then exhibited elimination kinetics typically observed for Compound 1. The term "ND" means not determined. The term "NA" means not applicable. The dose of each prodrug was normalized to the
Compound 1 dose. The values of the PK parameters for the prodrug form for Compounds 4a and 21a are based on the resulting accumulation and elimination of Compound 1.
Table 3 a Mouse IV
PK Parameters Cpd l Cpd 4a Cpd 21a
Cmax (ug/ml) 2.6 ND 11
AUC (ug-h/ml) 1.1 ND 28
Tl/2 (h) 1 ND 1.4
Tmax (h) 0.13 ND 1
MRT (h) ND 2.5
Dose (mg/kg) 2 ND 26
Normalized Dose (mg/kg) NA ND 17.5 Table 3b Mouse PO
PK Parameters Cpd l Cpd 4a Cpd 21a
Cmax (ug/ml) 5.9 8.3 14.3
AUC (ug-h/ml) 23 35 44
Tl/2 (h) 2.1 1.8 1.9
Tmax (h) 1.3 2 0.5
MRT (h) 3.4 3.1
Dose (mg/kg) 10 22 22
Normalized Dose (mg/kg) NA 15 15
Table 3 c
Rat IV
PK Parameters Cpd l Cpd 4a Cpd 21a
Cmax (ug/ml) 6.6 2.1 2.3
AUC (ug-h/ml) 14 7.8 9.2
Ti/2 (h) 4.5 4.3 4.1
Tmax (h) NA 0.4 0.27
MRT (h) 4.8 4.5
Dose (mg/kg) 2 2 2
Normalized Dose (mg/kg) NA 1.3 1.3
Table 3d
Dog IV
PK Parameters Cpd l Cpd 4a Cpd 21a
Cmax (ug/ml) 2.3 1.1 0.9 AUC (ug-h/ml) 2.8 2.4 4.2
Tl/2 (h) 1.8 3.1 3.3
Tmax (h) NA 1.0 0.58 MRT (h) 4.2 4.9 PK Parameters Cpd 1 Cpd 4a Cpd 21a
Dose (mg/kg) 1 2 2
Normalized Dose (mg/kg) NA 1.3 1.3
The above description is intended for illustrative purposes only, and does not limit the scope of the invention, which is defined in the following claims.

Claims

We Claim:
1. A compound having the Formula (I):
Figure imgf000041_0001
(I) wherein R is a leaving group that undergoes a reaction in a biological matrix to produce the active ingredient of the structure:
Figure imgf000041_0002
2. A compound having the Formula (II):
Figure imgf000041_0003
(H) wherein:
R1 is hydrogen or lower alkyl;
R2 is selected from the group consisting of
Figure imgf000041_0004
wherein, n is 0, 1 , 2, 3 or 4;
X is selected from the group consisting of amino optionally substituted by one or two lower alkyl; heterocyclyl optionally substituted by one or more lower alkyl; and -O-PO3H2 or an alkyl ester thereof; Y is selected from the group consisting of -CH2O-PO3H2 or an alkyl ester thereof, and -O-PO3H2 or an alkyl ester thereof;
R is hydrogen or lower alkyl; or a pharmaceutically acceptable salt thereof.
3. The compound of claim 2, wherein R1 is hydrogen or lower alkyl;
R2 is selected from the group consisting of
O O
/C-(CH2)n-X; and "^P-OR3
OH
wherein n is 1 ;
X is selected from the group consisting of amino optionally substituted by one or two lower alkyl; and, heterocyclyl, optionally substituted by one or more lower alkyl;
R3 is lower alkyl; or a pharmaceutically acceptable salt thereof.
4. The compound of claim 2, wherein R1 is hydrogen or methyl;
R2 is selected from the group consisting of
O O
/C-(CH2)n-X; and ^P-OR3
OH
wherein n is 1 ; X is selected from the group consisting of amino optionally substituted by one or two methyl; and, pyrrolidinyl, piperazinyl or morpholinyl, optionally substituted on pyrrolidinyl or piperazinyl by one methyl;
R3 is ethyl; or a pharmaceutically acceptable salt thereof.
5. The compound of claim 4, wherein X is selected from the group consisting of amino optionally substituted by one or two methyl; and, piperazinyl optionally substituted by one methyl.
6. A compound selected from the group consisting of:
Piperazin- 1 -yl-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
Piperazin- 1 -yl-acetic acid 1 -(acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro- 4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-ethyl ester,
Dimethylamino-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
Morpholin-4-yl-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4/f- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester, l-Methyl-pyrrolidine-2-carboxylic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
(4-Methyl-piperazin-l-yl)-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
(tert-Butoxycarbonyl-methyl-amino)-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2- methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl} -carbamoyloxy)-methyl ester,
Methylamino-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4/f- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester, (S)-Pyrrolidine- 1 ,2-dicarboxylic acid 2-[(acetyl- {(R)-3-[3-fluoro-4-(2-methyl- 2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl}-carbamoyloxy)-methyl] ester l-tert-buty\ ester,
(S)-Pyrrolidine-2-carboxylic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
4-(Bis-benzyloxy-phosphoryloxymethyl)-benzoic acid (acetyl- {(R)-3-[3-fluoro- 4-(2-methyl-2,6-dihydro-4/f-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl} -carbamoyloxy)-methyl ester,
4-Phosphonooxymethyl-benzoic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
4-(Bis-benzyloxy-phosphoryloxy)-benzoic acid (acetyl- {(R)-3-[3-fluoro-4-(2- methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl} -carbamoyloxy)-methyl ester,
4-Phosphonooxy-benzoic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro- 4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid di-te/t-butoxy- phosphoryloxymethyl ester,
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid 1 -(di-te/t-butoxy- phosphoryloxy)-ethyl ester,
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid phosphonooxymethyl ester,
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid 1 -phosphonooxy-ethyl ester,
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid benzyloxy-ethoxy- phosphoryloxymethyl ester,
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid 1 -(benzyloxy-ethoxy- phosphoryloxy)-ethyl ester,
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid ethoxy-hydroxy- phosphoryloxymethyl ester, Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid 1 -(ethoxy-hydroxy- phosphoryloxy)-ethyl ester,
(Di-tert-butoxy-phosphoryloxy)-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl- 2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl}-carbamoyloxy)-methyl ester, and
Phosphonooxy-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester.
7. The compound of claim 6, wherein the compound is selected from the group consisting of:
Piperazin- 1 -yl-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
Piperazin- 1 -yl-acetic acid 1 -(acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro- 4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-ethyl ester,
Dimethylamino-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
Morpholin-4-yl-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester, l-Methyl-pyrrolidine-2-carboxylic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
(4-Methyl-piperazin-l-yl)-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
Methylamino-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4/f- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
(S)-Pyrrolidine-2-carboxylic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
4-Phosphonooxymethyl-benzoic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester, 4-Phosphonooxy-benzoic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro- 4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid phosphonooxymethyl ester,
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid 1 -phosphonooxy-ethyl ester,
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid ethoxy-hydroxy- phosphoryloxymethyl ester,
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid 1 -(ethoxy-hydroxy- phosphoryloxy)-ethyl ester, and
Phosphonooxy-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester.
The compound of claim 7, wherein the compound is selected from the group consisting of:
Piperazin- 1 -yl-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
Piperazin- 1 -yl-acetic acid 1 -(acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro- 4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-ethyl ester,
Dimethylamino-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
(4-Methyl-piperazin-l-yl)-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2 -methyl-2,6- dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester,
Methylamino-acetic acid (acetyl- {(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H- pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}- carbamoyloxy)-methyl ester, and
Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4/f-pyrrolo[3,4-c]pyrazol-5- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -carbamic acid ethoxy-hydroxy- phosphoryloxymethyl ester.
9. A pharmaceutical formulation comprising a compound of claim 1 as an active pharmaceutical ingredient, and one or more pharmaceutically acceptable excipients.
10. A pharmaceutical formulation comprising a compound of claim 2 as an active pharmaceutical ingredient, and one or more pharmaceutically acceptable excipients.
PCT/US2007/073095 2006-07-27 2007-07-10 Antimicrobial oxazolidinone prodrugs Ceased WO2008014108A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82049706P 2006-07-27 2006-07-27
US60/820,497 2006-07-27
US84865906P 2006-10-02 2006-10-02
US60/848,659 2006-10-02

Publications (2)

Publication Number Publication Date
WO2008014108A2 true WO2008014108A2 (en) 2008-01-31
WO2008014108A3 WO2008014108A3 (en) 2008-03-20

Family

ID=38870255

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/073095 Ceased WO2008014108A2 (en) 2006-07-27 2007-07-10 Antimicrobial oxazolidinone prodrugs

Country Status (6)

Country Link
US (1) US7776855B2 (en)
AR (1) AR062131A1 (en)
CL (1) CL2007002200A1 (en)
PE (1) PE20080283A1 (en)
TW (1) TW200817407A (en)
WO (1) WO2008014108A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7538108B2 (en) 2005-01-19 2009-05-26 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7557210B2 (en) 2002-02-01 2009-07-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7582648B2 (en) 2003-07-30 2009-09-01 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US8158621B2 (en) 2002-07-29 2012-04-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
WO2014043272A1 (en) 2012-09-12 2014-03-20 Trius Therapeutics Inc. Tricyclic gyrase inhibitors for use as antibacterial agents

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9701847B2 (en) * 2012-12-21 2017-07-11 Mcp Ip, Llc Reinforced powder paint for composites
US20180344648A1 (en) * 2015-11-30 2018-12-06 Piramal Enterprises Limited Clobazam tablet formulation and process for its preparation
JP2024516114A (en) * 2021-04-07 2024-04-12 コスマス セラピューティックス ディベロップメント インコーポレイテッド Novel modulators of melatonin receptors and methods of making and using same - Patents.com

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3011499A (en) 1998-04-15 1999-11-01 Warner-Lambert Company Prodrugs of benzofuranylmethyl carbamate nk antagonists
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
CA2385071A1 (en) 1999-10-12 2001-04-19 Norman Kong Substituted pyrroles as antiproliferative agents for the treatment of cancer
US7265140B2 (en) 2003-09-23 2007-09-04 Pfizer Inc Acyloxymethylcarbamate prodrugs of oxazolidinones

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835430B2 (en) 2002-02-01 2014-09-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7557210B2 (en) 2002-02-01 2009-07-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US10709703B2 (en) 2002-02-01 2020-07-14 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US10682350B2 (en) 2002-02-01 2020-06-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9913842B2 (en) 2002-02-01 2018-03-13 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9416112B2 (en) 2002-02-01 2016-08-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9346765B2 (en) 2002-02-01 2016-05-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9018204B1 (en) 2002-02-01 2015-04-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US8158621B2 (en) 2002-07-29 2012-04-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7582648B2 (en) 2003-07-30 2009-09-01 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US8785437B2 (en) 2005-01-19 2014-07-22 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8476263B2 (en) 2005-01-19 2013-07-02 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8211888B2 (en) 2005-01-19 2012-07-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US9266912B2 (en) 2005-01-19 2016-02-23 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8211889B2 (en) 2005-01-19 2012-07-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7538108B2 (en) 2005-01-19 2009-05-26 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US9532998B2 (en) 2005-01-19 2017-01-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7989448B2 (en) 2005-01-19 2011-08-02 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US10577381B2 (en) 2005-01-19 2020-03-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7563892B1 (en) 2005-01-19 2009-07-21 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4 pyrimidinediamine compounds and their uses
WO2014043272A1 (en) 2012-09-12 2014-03-20 Trius Therapeutics Inc. Tricyclic gyrase inhibitors for use as antibacterial agents

Also Published As

Publication number Publication date
US7776855B2 (en) 2010-08-17
PE20080283A1 (en) 2008-04-10
TW200817407A (en) 2008-04-16
US20080027053A1 (en) 2008-01-31
WO2008014108A3 (en) 2008-03-20
AR062131A1 (en) 2008-10-15
CL2007002200A1 (en) 2008-02-08

Similar Documents

Publication Publication Date Title
US7776855B2 (en) Antimicrobial oxazolidinone prodrugs
EP2305657B1 (en) Oxazolidinone derivatives
DE69924751T2 (en) CEPHEM COMPOUNDS WITH AN IMIDAZO [4,5-B] PYRIDINIUM METHYL REST HAVING A WIDE ANTIBACTERIAL EFFECT SCOPE
JP6453222B2 (en) Preparation of diazabicyclooctane derivatives and their intermediates
CA2196862A1 (en) Substituted oxazolidinones
BG99833A (en) Benzoxazolyl- and benzothiazolyloxazolidinons
TW200305422A (en) Broad spectrum cefem compounds
US6214818B1 (en) Cephem compounds and pharmaceutical compositions containing the same
EP3898631B1 (en) Novel imidazopyrazine derivatives as antibacterials
KR20110067140A (en) Novel nitrogen-containing heterocyclic compounds, their preparation and their use as antibacterial agents
CN114981259A (en) Novel heterocyclic compound
EP2367820B1 (en) Novel antimicrobial agents
RU2412939C2 (en) N-formyl hydroxyamine derivatives
EP4161931B1 (en) Novel imidazopyrazine derivatives
KR20100138978A (en) 7-substituted derivatives of the novel 3-carboxy-oxadiazino-quinolones, methods for their preparation and their use as antibacterial agents
EP1721906A1 (en) 3-pyridinium methylcephem compound
WO2019186590A1 (en) Oxazolidinone antibiotic compounds and process of preparation
EP3717490B1 (en) Anti-bacterial heterocyclic compounds and their synthesis
EP2310395B1 (en) 9-substituted-b-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
JP3403173B2 (en) Carbapenem derivative and method for producing the same
HK40078454A (en) Novel heterocyclic compounds
HK40038969A (en) Peptide macrocycles against acinetobacter baumannii
HK1151521B (en) 9-substituted-b-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
WO2011084922A1 (en) Pro-drugs of (e) -7- (3- (2-amino-1-fluoroethylidene) piperidin-1-yl) -1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07812734

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07812734

Country of ref document: EP

Kind code of ref document: A2